NASDAQ:MDSO - Medidata Solutions Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$87.34 +3.50 (+4.17 %)
(As of 07/18/2018 02:57 AM ET)
Previous Close$83.84
Today's Range$84.52 - $88.09
52-Week Range$59.60 - $88.09
Volume849,000 shs
Average Volume606,501 shs
Market Capitalization$5.02 billion
P/E Ratio102.75
Dividend YieldN/A
Beta1.57
Medidata Solutions logoMedidata Solutions, Inc. provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management. It also provides professional services, such as implementation, sponsor enablement, strategic consulting, partner and ongoing support, and e-learning and training. The company markets and sells its cloud-based solutions through a direct sales force, as well as through relationships with contract research organizations (CROs) and other strategic partners. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; academic research centers, government, and other non-profit organizations; and CROs and other entities engaged in clinical trials. Medidata Solutions, Inc. was founded in 1999 and is headquartered in New York, New York.

Receive MDSO News and Ratings via Email

Sign-up to receive the latest news and ratings for MDSO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Prepackaged software
Sub-IndustryHealth Care Technology
SectorMedical
SymbolNASDAQ:MDSO
CUSIP58471A10
Phone212-918-1800

Debt

Debt-to-Equity Ratio0.18
Current Ratio1.63
Quick Ratio1.63

Price-To-Earnings

Trailing P/E Ratio102.75
Forward P/E Ratio114.92
P/E Growth5.44

Sales & Book Value

Annual Sales$545.53 million
Price / Sales9.48
Cash Flow$1.6005 per share
Price / Cash54.57
Book Value$8.51 per share
Price / Book10.26

Profitability

EPS (Most Recent Fiscal Year)$0.85
Net Income$44.38 million
Net Margins7.96%
Return on Equity11.36%
Return on Assets5.59%

Miscellaneous

Employees1,680
Outstanding Shares59,220,000
Market Cap$5,019.06

The Truth About Cryptocurrencies

Medidata Solutions (NASDAQ:MDSO) Frequently Asked Questions

What is Medidata Solutions' stock symbol?

Medidata Solutions trades on the NASDAQ under the ticker symbol "MDSO."

How were Medidata Solutions' earnings last quarter?

Medidata Solutions Inc (NASDAQ:MDSO) released its quarterly earnings data on Thursday, April, 19th. The company reported $0.40 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.05. The firm had revenue of $149.20 million for the quarter, compared to the consensus estimate of $146.73 million. Medidata Solutions had a net margin of 7.96% and a return on equity of 11.36%. The firm's revenue was up 16.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.31 earnings per share. View Medidata Solutions' Earnings History.

When is Medidata Solutions' next earnings date?

Medidata Solutions is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Medidata Solutions.

What price target have analysts set for MDSO?

14 brokers have issued 1-year price targets for Medidata Solutions' shares. Their forecasts range from $78.00 to $100.00. On average, they anticipate Medidata Solutions' stock price to reach $88.2143 in the next year. This suggests a possible upside of 1.0% from the stock's current price. View Analyst Ratings for Medidata Solutions.

What is the consensus analysts' recommendation for Medidata Solutions?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medidata Solutions in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Medidata Solutions' key competitors?

Who are Medidata Solutions' key executives?

Medidata Solutions' management team includes the folowing people:
  • Mr. Tarek A. Sherif, Co-Founder, Chairman & CEO (Age 56)
  • Mr. Glen M. De Vries, Co-Founder, Pres & Director (Age 46)
  • Mr. Rouven Bergmann, CFO & Chief Accounting Officer (Age 45)
  • Mr. Michael I. Otner, Exec. VP, Gen. Counsel & Sec. (Age 47)
  • Mr. Michael Pray, Exec. VP & GM of Global Sales (Age 52)

Has Medidata Solutions been receiving favorable news coverage?

Media headlines about MDSO stock have been trending positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Medidata Solutions earned a news sentiment score of 0.35 on Accern's scale. They also assigned news articles about the company an impact score of 46.03 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Medidata Solutions' major shareholders?

Medidata Solutions' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include American Capital Management Inc. (1.10%), Peregrine Capital Management LLC (0.51%), Copper Rock Capital Partners LLC (0.50%), Summit Creek Advisors LLC (0.28%), Bank of Montreal Can (0.04%) and Fortaleza Asset Management Inc. (0.00%). Company insiders that own Medidata Solutions stock include Carlos Dominguez, Eileen Schloss, Michael I Otner, Michael L Capone, Michael Pray, Robert Taylor, Rouven Bergmann, Steven Isaac Hirschfeld, Tarek Sherif and Vries Glen Michael De. View Institutional Ownership Trends for Medidata Solutions.

Which major investors are selling Medidata Solutions stock?

MDSO stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Bank of Montreal Can and Fortaleza Asset Management Inc.. Company insiders that have sold Medidata Solutions company stock in the last year include Carlos Dominguez, Michael I Otner, Michael L Capone, Michael Pray, Robert Taylor, Rouven Bergmann and Tarek Sherif. View Insider Buying and Selling for Medidata Solutions.

Which major investors are buying Medidata Solutions stock?

MDSO stock was acquired by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Summit Creek Advisors LLC and American Capital Management Inc.. View Insider Buying and Selling for Medidata Solutions.

How do I buy shares of Medidata Solutions?

Shares of MDSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Medidata Solutions' stock price today?

One share of MDSO stock can currently be purchased for approximately $87.34.

How big of a company is Medidata Solutions?

Medidata Solutions has a market capitalization of $5.02 billion and generates $545.53 million in revenue each year. The company earns $44.38 million in net income (profit) each year or $0.85 on an earnings per share basis. Medidata Solutions employs 1,680 workers across the globe.

How can I contact Medidata Solutions?

Medidata Solutions' mailing address is 350 HUDSON ST. 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 212-918-1800 or via email at [email protected]


MarketBeat Community Rating for Medidata Solutions (NASDAQ MDSO)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  383 (Vote Outperform)
Underperform Votes:  262 (Vote Underperform)
Total Votes:  645
MarketBeat's community ratings are surveys of what our community members think about Medidata Solutions and other stocks. Vote "Outperform" if you believe MDSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDSO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.